Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID‐19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series

Table 5 Hospitalization days in different treatment groups or in patients with or without Arbidol based on gender, age and maximum body temperature

Feature	Without Arbidol (n = 49)	With Arbidol (n = 72)	p value	OR (95% CI)
Hospital day [M (IQR)]	18 (16, 20)	17 (14, 21)	0.25

	Control (n = 21)	Other antiviral drugs (n = 28)	Arbidol only (n = 48)	Arbidol + other antiviral drugs (n = 24)
Hospital day [M (IQR)]	19 (17, 21)	18 (14, 20)	15.5 (12, 20) *^a	19.5 (17, 21)

Male	Without Arbidol (n = 24)	With Arbidol (n = 40)	p value
Hospital day [M (IQR)]	19 (14.5, 20)	16 (14, 20)	0.25

Female	Without Arbidol (n = 25)	With Arbidol (n = 32)	p value
Hospital day [M (IQR)]	18 (16.5, 20)	18 (13.3, 21)	0.75

≤ 50 years	Without Arbidol (n = 23)	With Arbidol (n = 49)	p value
Hospital day [M (IQR)]	18 (17, 20)	17 (13.5, 20.5)	0.04*

> 50 years	Without Arbidol (n = 26)	With Arbidol (n = 23)	p value
Hospital day [M (IQR)]	18 (14, 20)	18 (14, 21)	0.94

≤ 38.5C	Without Arbidol (n = 33)	With Arbidol (n = 51)	p value
Hospital day [M (IQR)]	19 (16.5, 20)	18 (14, 21)	0.23

> 38.5C	Without Arbidol (n = 16)	With Arbidol (n = 21)	p value
Hospital day [M (IQR)]	17.5 (14, 19)	17 (12.5, 20)	0.73

ISSN: 1743-422X